JP2023546536A - 線維症を処置する方法 - Google Patents

線維症を処置する方法 Download PDF

Info

Publication number
JP2023546536A
JP2023546536A JP2023547328A JP2023547328A JP2023546536A JP 2023546536 A JP2023546536 A JP 2023546536A JP 2023547328 A JP2023547328 A JP 2023547328A JP 2023547328 A JP2023547328 A JP 2023547328A JP 2023546536 A JP2023546536 A JP 2023546536A
Authority
JP
Japan
Prior art keywords
fibrosis
gli1
lung
hydrogen
taladegib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547328A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546536A5 (https=
Inventor
ロス リオス， ミゲル デ
ジョン フッド，
アニータ ディフランチェスコ，
Original Assignee
エンデバー バイオメディシンズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エンデバー バイオメディシンズ， インコーポレイテッド filed Critical エンデバー バイオメディシンズ， インコーポレイテッド
Publication of JP2023546536A publication Critical patent/JP2023546536A/ja
Publication of JP2023546536A5 publication Critical patent/JP2023546536A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023547328A 2020-10-13 2021-10-13 線維症を処置する方法 Pending JP2023546536A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063091128P 2020-10-13 2020-10-13
US63/091,128 2020-10-13
PCT/US2021/054713 WO2022081661A1 (en) 2020-10-13 2021-10-13 Methods of treating fibrosis

Publications (2)

Publication Number Publication Date
JP2023546536A true JP2023546536A (ja) 2023-11-02
JP2023546536A5 JP2023546536A5 (https=) 2024-11-14

Family

ID=81209448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547328A Pending JP2023546536A (ja) 2020-10-13 2021-10-13 線維症を処置する方法

Country Status (8)

Country Link
US (4) US11628167B2 (https=)
EP (1) EP4229828A4 (https=)
JP (1) JP2023546536A (https=)
KR (1) KR20230107568A (https=)
CN (1) CN116349204A (https=)
AU (1) AU2021360767A1 (https=)
CA (1) CA3198661A1 (https=)
WO (1) WO2022081661A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
JP2023546536A (ja) 2020-10-13 2023-11-02 エンデバー バイオメディシンズ， インコーポレイテッド 線維症を処置する方法
AU2024230449A1 (en) * 2023-02-28 2025-09-11 Endeavor Biomedicines, Inc. Methods of treating fibrosis
WO2025188802A1 (en) 2024-03-05 2025-09-12 Endeavor Biomedicines, Inc. Methods of improving lung function
WO2025189041A1 (en) * 2024-03-07 2025-09-12 Endeavor Biomedicines, Inc. Methods of treating fibrosis
WO2025242197A1 (zh) * 2024-05-24 2025-11-27 成都思倍博医药科技有限公司 氘代的Hedgehog通路SMO受体抑制剂

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530705A (ja) * 2009-06-19 2012-12-06 イーライ リリー アンド カンパニー 二置換フタラジンヘッジホッグ経路アンタゴニスト
US20200000784A1 (en) * 2018-06-29 2020-01-02 The Trustees Of Indiana University Materials and methods for treating valvular heart diseases

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (https=) 1977-06-03 1981-03-07 Pfizer
MY117098A (en) 1996-01-15 2004-05-31 Janssen Pharmaceutica Nv Angiogenesis inhibiting pyridazinamines
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
ATE283700T1 (de) 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
EP1496905B1 (en) 2002-04-22 2008-08-13 Johns Hopkins University School of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
WO2005033288A2 (en) 2003-09-29 2005-04-14 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
WO2006004589A2 (en) 2004-05-08 2006-01-12 Neurogen Corporation 3-aryl-5,6-disubstituted pyridazines
ES2377430T3 (es) 2004-09-02 2012-03-27 Genentech, Inc. Inhibidores piridílicos de la señalización de hedgehog
EP1900731A1 (de) 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
CA2681162C (en) 2007-03-15 2015-11-24 Novartis Ag Benzyl and pyridine derivatives as modulators of hedgehog pathway
US8153633B2 (en) 2007-06-25 2012-04-10 Amgen Inc. Phthalazine compounds, compositions and methods of use
US8222251B2 (en) 2007-09-07 2012-07-17 Amgen Inc. Pyridopyridazine compounds, compositions and methods of use
UA102250C2 (ru) 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
WO2010017240A2 (en) 2008-08-04 2010-02-11 Amgen Inc. Aurora kinase modulators and methods of use
MX2011004683A (es) 2008-11-03 2011-06-20 Lilly Co Eli Antagonistas de la via hedgehog de ftalazina disustituida.
BRPI0921777A2 (pt) 2008-11-17 2016-01-12 Lilly Co Eli antagonistas da via hedgehog de piridazina tetrassubstituída
KR101342184B1 (ko) 2008-11-17 2013-12-19 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
US20110183948A1 (en) 2010-01-15 2011-07-28 Infinity Pharmaceuticals, Inc. Treatment of fibrotic conditions using hedgehog inhibitors
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
US9970935B2 (en) * 2014-02-06 2018-05-15 The Brigham And Women's Hospital, Inc. Uses of GLI1 in detecting tissue fibrosis
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
JP2018535238A (ja) 2015-11-30 2018-11-29 イグナイタ インコーポレイテッド 局所製剤
EP3536320A4 (en) * 2016-11-04 2020-07-29 Impact Therapeutics, Inc APPLICATION OF A HEDGEHOG TRACT INHIBITOR FOR THE TREATMENT OF FIBROTIC DISEASES
EP3823618A1 (en) * 2018-07-19 2021-05-26 Varian Medical Systems, Inc. Methods of use of ultra-high dose rate radiation and therapeutic agents
JP2023546536A (ja) 2020-10-13 2023-11-02 エンデバー バイオメディシンズ， インコーポレイテッド 線維症を処置する方法
US12605377B2 (en) 2020-10-13 2026-04-21 Endeavor Biomedicines, Inc. Methods of treating fibrosis
AU2024230449A1 (en) 2023-02-28 2025-09-11 Endeavor Biomedicines, Inc. Methods of treating fibrosis

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012530705A (ja) * 2009-06-19 2012-12-06 イーライ リリー アンド カンパニー 二置換フタラジンヘッジホッグ経路アンタゴニスト
US20200000784A1 (en) * 2018-06-29 2020-01-02 The Trustees Of Indiana University Materials and methods for treating valvular heart diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HORN, A. ET AL.: "Inhibition of hedgehog signalling prevents experimental fibrosis and induces regression of establish", ANNALS OF THE RHEUMATIC DISEASES, vol. 71, no. 5, JPN6025044078, 2012, pages 785 - 789, ISSN: 0005718012 *
UENO, H. ET AL.: "A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with", INVESTIGATIONAL NEW DRUGS, vol. 36, no. 4, JPN6025044079, 2018, pages 647 - 656, ISSN: 0005718011 *

Also Published As

Publication number Publication date
CN116349204A (zh) 2023-06-27
CA3198661A1 (en) 2022-04-21
US12213974B2 (en) 2025-02-04
US20230201195A1 (en) 2023-06-29
US20240342170A1 (en) 2024-10-17
KR20230107568A (ko) 2023-07-17
AU2021360767A1 (en) 2023-04-27
US12295954B2 (en) 2025-05-13
US11628167B2 (en) 2023-04-18
EP4229828A4 (en) 2024-08-28
EP4229828A1 (en) 2023-08-23
AU2021360767A9 (en) 2024-02-08
WO2022081661A1 (en) 2022-04-21
US20220265650A1 (en) 2022-08-25
US20250235452A1 (en) 2025-07-24

Similar Documents

Publication Publication Date Title
US12213974B2 (en) Methods of treating fibrosis
US12605377B2 (en) Methods of treating fibrosis
JP6170040B2 (ja) ピルフェニドン及び選択された患者における抗線維化療法
EP4673129A1 (en) Methods of treating fibrosis
JP2018501217A (ja) 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン
JP2020529975A (ja) コカイン使用の低減又はコカイン使用再燃の予防におけるマボグルラントの使用
CN120500294A (zh) 抗trem2抗体和其用途
US20200368246A1 (en) Combination therapy targeting cancer associated with the hedgehog pathway
JP7794807B2 (ja) 気道疾患の治療に使用するための（１ｒ，３ｓ）－３－（（５－シアノ－４－フェニルチアゾール－２－イル）カルバモイル）シクロペンタン－１－カルボン酸およびその誘導体
Sugihara et al. 24-h bronchodilator efficacy of single doses of indacaterol in Japanese patients with asthma: A comparison with placebo and salmeterol
Hendeles et al. Response to inhaled albuterol during nocturnal asthma
CN120265291A (zh) 喹唑啉酮化合物的新用途和制剂
EP4460305A1 (en) Methods of treating idiopathic pulmonary fibrosis with deupirfenidone
CA2753754C (en) Methods for treating schizophrenia
WO2020234780A1 (en) Methods of treating asthma using a bruton's tyrosine kinase inhibitor
TW202535397A (zh) 給藥方案
RU2804834C2 (ru) Применение мавоглуранта при снижении употребления кокаина или при предупреждении рецидива употребления кокаина
WO2026092748A1 (zh) 雄性激素合成抑制剂与parp抑制剂联合用于治疗前列腺癌
WO2026052068A1 (zh) 药物组合物的用途
WO2023108140A1 (en) Method of treating cancer having an activated hedgehog pathway
JP2005531622A5 (https=)
Liu The safety and necessity of Sugammadex in neuromuscular blockade reversal
Kaiser Relationship of patient characteristics and process of care characteristics to post-operative pain outcomes in the orthopedic patient
WO2014130910A1 (en) Treatment for substance use disorders and stress disorders

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241011

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260422